Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions - 21/08/11
, Arnon D. Cohen, MD, MPH a, Nili Grossman, PhD b
Reprint requests: Sima Halevy, MD, Department of Dermatology, Soroka University Medical Center, Beer-Sheva 84101, Israel.Beer-Sheva, Israel
Abstract |
Background |
Drug-specific T cells are involved in the pathogenesis of cutaneous adverse drug reactions (CADRs).
Objective |
We sought to evaluate the diagnostic role of in vitro drug-induced release of interferon gamma in CADRs.
Methods |
The study group consisted of 36 patients with CADRs after intake of 106 drugs that were classified into 3 categories of drug suspicion: high, possible, and low. The control group consisted of 22 individuals taking a similar profile of 54 drugs, without CADRs. In vitro drug-induced interferon gamma release was determined by enzyme-linked immunosorbent assay in culture supernatants after incubation of peripheral blood lymphocytes with parent drug compounds. The in vitro tests were conducted after the acute phase of the CADRs. In vitro tests were compared with in vivo withdrawal and/or challenge drug tests.
Results |
Positive interferon gamma tests were recorded in 77.8% of the patients for 49.0% of the drugs. The proportion of positive interferon gamma tests was directly associated with the degree of drug suspicion (64.4%, 36.4%, and 27.8% for high, possible, and low, respectively). There were significantly more positive tests for high- compared with low-suspicion drugs (P=.001). The degree of agreement between the results of the in vitro interferon gamma release tests and the in vivo tests was intermediate to good (kappa=0.47).
Conclusion |
In vitro drug-induced interferon gamma release may help to identify the responsible drug in CADRs.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. Conflicts of interest: None identified. Presented in part at the Fifth International Congress on Cutaneous Adverse Drug Reactions, Satellite Congress of the 32nd ESDR Annual Meeting, Palexpo Geneva, Switzerland on September 18-19, 2002; published as an Abstract (Halevy S, Cohen AD, Grossman N. Interferon-γ release from peripheral blood lymphocytes following in vitro challenge with drugs in patients with cutaneous adverse drug reactions—comparison with in vivo tests [abstract]. J Invest Dermatol 2002;119:726.) |
Vol 52 - N° 2
P. 254-261 - février 2005 Retour au numéro
Article précédent
- Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination
- Kim A. Papp, Kristine Breuer, Michael Meurer, Jean-Paul Ortonne, Paul C. Potter, Yves de Prost, Miles J. Davidson, Nathalie Barbier, Hans-Peter Goertz, Carle Paul
- Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis
- Srdjan Prodanowich, Fangchao Ma, J. Richard Taylor, Candido Pezon, Tahira Fasihi, Robert S. Kirsner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?